EP0833663A4 - Carbohydrate-mediated coupling of peptides to immunoglobulins - Google Patents

Carbohydrate-mediated coupling of peptides to immunoglobulins

Info

Publication number
EP0833663A4
EP0833663A4 EP96916458A EP96916458A EP0833663A4 EP 0833663 A4 EP0833663 A4 EP 0833663A4 EP 96916458 A EP96916458 A EP 96916458A EP 96916458 A EP96916458 A EP 96916458A EP 0833663 A4 EP0833663 A4 EP 0833663A4
Authority
EP
European Patent Office
Prior art keywords
immunoglobulins
carbohydrate
peptides
mediated coupling
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96916458A
Other languages
German (de)
French (fr)
Other versions
EP0833663A1 (en
Inventor
Constantin A Bona
Y C Lee
Teodor-Doru Brumeanu
Philip Dehazya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0833663A1 publication Critical patent/EP0833663A1/en
Publication of EP0833663A4 publication Critical patent/EP0833663A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP96916458A 1995-05-15 1996-05-13 Carbohydrate-mediated coupling of peptides to immunoglobulins Withdrawn EP0833663A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44132895A 1995-05-15 1995-05-15
US47742495A 1995-06-07 1995-06-07
US477424 1995-06-07
PCT/US1996/006756 WO1996036357A1 (en) 1995-05-15 1996-05-13 Carbohydrate-mediated coupling of peptides to immunoglobulins
US441328 2003-05-20

Publications (2)

Publication Number Publication Date
EP0833663A1 EP0833663A1 (en) 1998-04-08
EP0833663A4 true EP0833663A4 (en) 1999-04-07

Family

ID=27032769

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96916458A Withdrawn EP0833663A4 (en) 1995-05-15 1996-05-13 Carbohydrate-mediated coupling of peptides to immunoglobulins

Country Status (4)

Country Link
EP (1) EP0833663A4 (en)
AU (1) AU5920096A (en)
CA (1) CA2227326A1 (en)
WO (1) WO1996036357A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
SG159381A1 (en) * 2001-10-10 2010-03-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
DK2279755T3 (en) * 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodeling and glycoconjugation of fibroblast growth factor (FGF)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ES2420581T3 (en) 2003-03-14 2013-08-26 Biogenerix Gmbh Branched water soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05010773A (en) 2003-04-09 2005-12-12 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005014049A2 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005070138A2 (en) 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP4951527B2 (en) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー GlycoPEGylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス Purification method for polypeptide conjugates
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101965200B (en) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088695A2 (en) * 1982-03-09 1983-09-14 Cytogen Corporation Antibody conjugates
EP0326322A1 (en) * 1988-01-27 1989-08-02 Eli Lilly And Company Antibody conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874813A (en) * 1987-02-09 1989-10-17 Shannessy Daniel J O Proteins bound to a marker or solid phase support matrix using a hydrazone linkage
US5258501A (en) * 1988-11-25 1993-11-02 Slobodan Barbaric Stabilization of glycoproteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088695A2 (en) * 1982-03-09 1983-09-14 Cytogen Corporation Antibody conjugates
EP0326322A1 (en) * 1988-01-27 1989-08-02 Eli Lilly And Company Antibody conjugates

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BRUMEANU T D ET AL: "Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus.", JOURNAL OF EXPERIMENTAL MEDICINE 178 (5). 1993. 1795-1799. ISSN: 0022-1007, XP000567066 *
BRUMEANU T-D ET AL: "Presentation of a viral peptide assembled on the carbohydrate moieties of immunoglobulin does not require processing.", EUROPEAN JOURNAL OF IMMUNOLOGY 27 (9). 1997. 2408-2416. ISSN: 0014-2980, XP002088231 *
BRUMEANU, T.-D. ET AL: "Enzymically mediated, glycosidic conjugation of immunoglobulins with viral epitopes", J. IMMUNOL. METHODS (1995), 183(2), 185-97 CODEN: JIMMBG;ISSN: 0022-1759, XP004021011 *
CABACUNGAN J C ET AL: "Amine boranes as alternative reducing agents for reductive alkylation of proteins", ANAL. BIOCHEM., vol. 124, no. 2, - 1982, pages 272 - 278, XP002084857 *
MITCHELL R N ET AL: "THE USE OF RADIOACTIVE CYSTEINE METHYL ESTER FOR LABELING GLYCOSYLATED MOLECULES OXIDIZED BY PER IODATE OR NEURAMINIDASE PLUS GALACTOSE OXIDASE.", ARCH BIOCHEM BIOPHYS 229 (2). 1984. 544-554. CODEN: ABBIA4 ISSN: 0003-9861, XP002088227 *
O'SHANESSY D J ET AL: "Specific conjugation reactions of the oligosaccharide moieties of immunoglobulins", J. APPL. BIOCHEM., vol. 7, no. 4-5, 1985, pages 347-355, XP002088228 *
See also references of WO9636357A1 *
SOLCIA E ET AL: "Cathepsin E in antigen-presenting Langerhans and interdigitating reticulum cells. Its possible role in antigen processing", EUR. J. HISTOCHEM., vol. 37, no. 1, - 1993, pages 19 - 26, XP002088229 *
YONEZAWA, SATOSHI ET AL: "Cathepsin E from rat neutrophils: its properties and possible relations to cathepsin D-like and cathepsin E -like acid proteinases", ARCH. BIOCHEM. BIOPHYS. (1987), 256(2), 499-508 CODEN: ABBIA4;ISSN: 0003-9861, XP002088230 *

Also Published As

Publication number Publication date
EP0833663A1 (en) 1998-04-08
AU5920096A (en) 1996-11-29
CA2227326A1 (en) 1996-11-21
WO1996036357A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
EP0833663A4 (en) Carbohydrate-mediated coupling of peptides to immunoglobulins
GB9526560D0 (en) Use of 2-Amino-Heterocycles
GB2320005B (en) Orientation of cans
GB9501229D0 (en) Improvements relating to magnetic coupling systems
IL116924A (en) Preparation of n-aryl - and n-hetarylhydroxylamines
SG42329A1 (en) Use of phenylcyclohexylcarboxamides
GB2302389B (en) Joint
ZA967742B (en) The use of cytohesin-ph peptides for influencing the ability of integrins to adhere
HUP9601885A3 (en) Injection suspension free of sodiumbentonit
IL117786A (en) Preparation of alpha-bisoximes
EG20782A (en) Process of preparation streptogramines
GB2303807B (en) Flange to pipe joint
GB2299974B (en) Improvements relating to vessels
PL316288A1 (en) Peptides suitable to inhibit liberation of pepsin
IL118238A0 (en) Synthesis of benzoquinolinones
GB9514072D0 (en) Preparation of thionucleosides
CA76199S (en) Set of dishes
TW296130U (en) Improved structure of connector
HU9503668D0 (en) Attaching means of hooses
HU9500815D0 (en) Means of coupling of non-thread connections
ZA962440B (en) Destressing of railtracks
IL115554A0 (en) Earthquake-proofing of structures
PL311976A1 (en) Closed-profile shape of double-o type
ZA965813B (en) Novel process for the preparation of peptides and n-carba-moyl-protected peptides
TW346261U (en) Panel of connector

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990216

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990519

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 19991130